BJMO - volume 19, issue 2, march 2025
W. Lybaert MD, L. Mariën MSc, O. Islam MD, S. Chhajlani MD, C. De Weerdt MSc, I. Nietvelt MSc, S. Raats MSc, L. Verbruggen PhD, T. Vandamme MD, PhD
During the ESMO Conference in Barcelona in 2024, two important phase 3 studies in the field of neuro-endocrine tumours (NET) that were presented earlier this year were updated and also published subsequently. The NETTER-2 trial is shifting [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) to the first-line treatment setting of patients with advanced, well-differentiated grade 2 and grade 3 gastro-enteropancreatic (GEP) NET; the CABINET trial is adding cabozantinib as targeted systemic therapy for previously treated, progressive advanced extrapancreatic and pancreatic NET.
In this report, these two practice-changing NET trials will be discussed in depth, with comments on the clinical relevance and the outstanding questions.
(BELG J MED ONCOL 2025;19(2):78–82)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
